|

Natural Killer Cell Therapy Clinical Trials

2 actively recruiting trials across 1 location

▼ -1 trial since June 2026

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Kari Kendra1
  • John Reneau1

Indications

  • Cancer2
  • Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma1
  • Refractory Adult T-Cell Leukemia/Lymphoma1
  • Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma1
  • Recurrent Adult T-Cell Leukemia/Lymphoma1

Columbus, Ohio2 trials

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Ohio State University Comprehensive Cancer Center

Phase 1/2
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.